A Second Life for Bayer’s Diabetes Drug in China

China offers many different opportunities to global pharma – inexpensive APIs, drug development, a large market, to name a few very broad categories. For Bayer, China has given a second life to a 17-year-old diabetes drug, Glucobay. Glucobay, long off patent, is almost forgotten in the US. But it provided Bayer China with $283 million in revenues last year, an increase of 22% over the year before. More details.... Stock Symbol: (XETRA: BAY)     Share this with colleagues: